Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance

다국어 초록 (Multilingual Abstract)

Background/Aims: Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in Japan. We present an interim report of the ongoing PMS.Methods: Patients received 200 mg of subcutaneous GLM at week 0, 100 mg at week 2, and 100 mg 4 weekly thereafter. The safety analysis set included 392 patients with UC, and the effectiveness analysis set 387 patients. Safety and effectiveness were assessed at week 6.Results: Adverse drug reactions (ADRs) were reported in 8.2% (32/392) and serious ADRs in 4.6% (18/392). The most frequent ADRs were infection and infestation (3.3%), with herpes zoster being the most common. ADRs were significantly higher in patients with concomitant corticosteroid use (odds ratio [OR], 3.45; 95% confidence interval [CI], 1.40–9.68). No significant difference in ADR incidence was observed between patients aged ≥65 and <65 years (OR, 1.23; 95% CI, 0.35–3.47). Six-week effectiveness of GLM was confirmed by a decrease in the partial Mayo score (–2.3; 95% CI, –2.6 to –2.1) and C-reactive protein levels (–0.64; 95% CI, –0.92 to –0.36), including in the biologics-experienced population.Conclusions: The safety and effectiveness of GLM at week 6 in a real-world setting were demonstrated in patients with UC in Japan. ADR patterns were consistent with previous reports with no new safety signals. Concomitant corticosteroid use may be associated with increased ADR incidence. The final results of the ongoing PMS are necessary for further evaluation.

참고문헌 (Reference)

1 Sands BE, "Ustekinumab as induction and maintenance therapy for ulcerative colitis" 381 : 1201-1214, 2019

2 Lewis JD, "Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis" 14 : 1660-1666, 2008

3 Ungaro R, "Ulcerative colitis" 389 : 1756-1770, 2017

4 Kobayashi T, "Ulcerative colitis" 6 : 74-, 2020

5 Sandborn WJ, "Tofacitinib as induction and maintenance therapy for ulcerative colitis" 376 : 1723-1736, 2017

6 Morin C, "Systemic glucocorticoid therapy : risk factors for reported adverse events and beliefs about the drug : a cross-sectional online survey of 820 patients" 34 : 2119-2126, 2015

7 Gisbert JP, "Systematic review with meta-analysis : the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed" 41 : 613-623, 2015

8 Sandborn WJ, "Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis" 146 : 96-109, 2014

9 Sandborn WJ, "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis" 146 : 85-95, 2014

10 Brunner HI, "Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial" 77 : 21-29, 2018

11 Feuerstein JD, "Spotlight : management of moderate-to-severe ulcerative colitis" 158 : 1464-, 2020

12 "Simponi Interview Form registered in PMDA search system for prescription drugs"

13 Toruner M, "Risk factors for opportunistic infections in patients with inflammatory bowel disease" 134 : 929-936, 2008

14 Bossa F, "Real-life effectiveness and safety of golimumab and its predictors of response in patients with ulcerative colitis" 65 : 1767-1776, 2020

15 Vermeire S, "Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis : a randomized crossover study" 12 : 1193-1202, 2018

16 Curtis JR, "Population-based assessment of adverse events associated with long-term glucocorticoid use" 55 : 420-426, 2006

17 Seddik M, "Pneumocystis jiroveci(carinii)pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn’s disease" 10 : 436-437, 2004

18 Harbord M, "Part 2 : current management" 11 : 769-784, 2017

19 Mitoma H, "Molecular mechanisms of action of anti-TNF-α agents : comparison among therapeutic TNF-α antagonists" 101 : 56-63, 2018

20 Billmeier U, "Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases" 22 : 9300-9313, 2016

21 Ananthakrishnan AN, "Management of inflammatory bowel disease in the elderly patient : challenges and opportunities" 23 : 882-893, 2017

22 Higashiyama M, "Management of elderly ulcerative colitis in Japan" 54 : 571-586, 2019

23 Long MD, "Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease" 37 : 420-429, 2013

24 Ueno F, "Impact of inflammatory bowel disease on Japanese patients’ quality of life : results of a patient questionnaire survey" 52 : 555-567, 2017

25 Winthrop KL, "Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib" 24 : 2258-2265, 2018

26 Kavanaugh A, "Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study" 60 : 976-986, 2009

27 Probert CS, "Golimumab induction and maintenance for moderate to severe ulcerative colitis : results from GO-COLITIS(Golimumab : a phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)" 5 : e000212-, 2018

28 Kay J, "Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study" 58 : 964-975, 2008

29 Dragoni G, "Golimumab in inflammatory bowel diseases : present and future scenarios" 12 : 1-9, 2019

30 Samaan MA, "Golimumab : early experience and medium-term outcomes from two UK tertiary IBD centres" 9 : 221-231, 2018

31 Matsuoka K, "Evidence-based clinical practice guidelines for inflammatory bowel disease" 53 : 305-353, 2018

32 Zammarchi I, "Elderly-onset vs adult-onset ulcerative colitis : a different natural history?" 20 : 147-, 2020

33 Inman RD, "Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial" 58 : 3402-3412, 2008

34 Hibi T, "Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)" 52 : 1101-1111, 2017

35 Olivera P, "Effectiveness of golimumab in ulcerative colitis : a review of the real world evidence" 51 : 327-334, 2019

36 Tursi A, "Effectiveness and safety of golimumab in treating outpatient ulcerative colitis: a real-life prospective, multicentre, observational study in primary inflammatory bowel diseases centers" 26 : 239-244, 2017

37 Gemayel NC, "Dose escalation and switching of biologics in ulcerative colitis : a systematic literature review in real-world evidence" 35 : 1911-1923, 2019

38 Friedrich M, "Cytokine networks in the pathophysiology of inflammatory bowel disease" 50 : 992-1006, 2019

39 Truelove SC, "Cortisone in ulcerative colitis; final report on a therapeutic trial" 2 : 1041-1048, 1955

40 Singh S, "Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases : a systematic review and meta-analysis" 18 : 69-81, 2020

41 Taxonera C, "Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis" 23 : 1394-1402, 2017

42 Christensen KR, "Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab : a Danish single-center cohort study" 50 : 1018-1024, 2015

43 Orlandini B, "Clinical efficacy and safety of golimumab in biologically experienced and naïve patients with active ulcerative colitis : a real-life experience from two Italian IBD centers" 19 : 468-474, 2018

44 Komoto S, "Clinical differences between elderly-onset ulcerative colitis and non-elderly-onset ulcerative colitis : a nationwide survey data in Japan" 33 : 1839-1843, 2018

45 Kojima K, "Clinical characteristics and risk factors for pneumocystis jirovecii pneumonia during immunosuppressive treatment in patients with ulcerative colitis : a retrospective study" 29 : 167-173, 2020

46 Shealy DJ, "Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α" 2 : 428-439, 2010

47 Yarlas A, "Burden of ulcerative colitis on functioning and well-being : a systematic literature review of the SF-36® health survey" 12 : 600-609, 2018

48 Cottone M, "Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease" 9 : 30-35, 2011

49 Taxonera C, "Adalimumab maintenance treatment in ulcerative colitis : outcomes by prior anti-TNF use and efficacy of dose escalation" 62 : 481-490, 2017

50 Singh S, "AGA technical review on the management of moderate to severe ulcerative colitis" 158 : 1465-1496, 2020